Rodman & Renshaw Downgrades Karyopharm Therapeutics to Neutral
Rodman & Renshaw analyst Michael King downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral.
Share
Why It Matters
An expert analyst changed his mind about Karyopharm. He thinks the stock is not a good buy right now, even though he liked it before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.